chloroquine has been researched along with Parkinson Disease in 7 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The autophagy-lysosome pathway (ALP) regulates intracellular homeostasis of the cytosolic protein SNCA/alpha-synuclein and is impaired in synucleinopathies, including Parkinson disease and dementia with Lewy bodies (DLB)." | 3.88 | Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. ( Adame, A; Barkovits, K; Bergmann, A; Buzás, EI; Emmanouilidou, E; Galasko, D; Kittel, A; Klucken, J; Lie, DC; Marcus, K; Marxreiter, F; Masliah, E; Menges, S; Minakaki, G; Mollenhauer, B; Rockenstein, E; Schaeffner, I; Schlötzer-Schrehardt, U; Vekrellis, K; Winkler, J; Xiang, W, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Nguyen, DT | 1 |
| Iqbal, J | 1 |
| Han, J | 1 |
| Pierens, GK | 1 |
| Wood, SA | 1 |
| Mellick, GD | 1 |
| Feng, Y | 1 |
| Kartik, S | 1 |
| Pal, R | 1 |
| Chaudhary, MJ | 1 |
| Nath, R | 1 |
| Kumar, M | 1 |
| Binwal, M | 1 |
| Bawankule, DU | 1 |
| Aguilar, JI | 1 |
| Cheng, MH | 1 |
| Font, J | 1 |
| Schwartz, AC | 1 |
| Ledwitch, K | 1 |
| Duran, A | 1 |
| Mabry, SJ | 1 |
| Belovich, AN | 1 |
| Zhu, Y | 1 |
| Carter, AM | 1 |
| Shi, L | 1 |
| Kurian, MA | 1 |
| Fenollar-Ferrer, C | 1 |
| Meiler, J | 1 |
| Ryan, RM | 1 |
| Mchaourab, HS | 1 |
| Bahar, I | 1 |
| Matthies, HJ | 1 |
| Galli, A | 1 |
| Minakaki, G | 1 |
| Menges, S | 1 |
| Kittel, A | 1 |
| Emmanouilidou, E | 1 |
| Schaeffner, I | 1 |
| Barkovits, K | 1 |
| Bergmann, A | 1 |
| Rockenstein, E | 1 |
| Adame, A | 1 |
| Marxreiter, F | 1 |
| Mollenhauer, B | 1 |
| Galasko, D | 1 |
| Buzás, EI | 1 |
| Schlötzer-Schrehardt, U | 1 |
| Marcus, K | 1 |
| Xiang, W | 1 |
| Lie, DC | 1 |
| Vekrellis, K | 1 |
| Masliah, E | 1 |
| Winkler, J | 1 |
| Klucken, J | 1 |
| Kim, CH | 1 |
| Han, BS | 1 |
| Moon, J | 1 |
| Kim, DJ | 1 |
| Shin, J | 1 |
| Rajan, S | 1 |
| Nguyen, QT | 1 |
| Sohn, M | 1 |
| Kim, WG | 1 |
| Han, M | 1 |
| Jeong, I | 1 |
| Kim, KS | 2 |
| Lee, EH | 1 |
| Tu, Y | 1 |
| Naffin-Olivos, JL | 1 |
| Park, CH | 1 |
| Ringe, D | 1 |
| Yoon, HS | 1 |
| Petsko, GA | 1 |
| Ohta, E | 1 |
| Kubo, M | 1 |
| Obata, F | 1 |
| Vaĭnshtok, AB | 1 |
7 other studies available for chloroquine and Parkinson Disease
| Article | Year |
|---|---|
Chemical constituents from Macleaya cordata (Willd) R. Br. and their phenotypic functions against a Parkinson's disease patient-derived cell line.
Topics: Alkaloids; Cell Line; Circular Dichroism; Density Functional Theory; Humans; Lysosomes; Magnetic Res | 2020 |
Neuroprotective role of chloroquine via modulation of autophagy and neuroinflammation in MPTP-induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autophagy; Chloroquine; Disease Models, Anima | 2023 |
Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile Parkinsonism-Dystonia.
Topics: Animals; Chloroquine; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; | 2021 |
Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype.
Topics: alpha-Synuclein; Animals; Autophagosomes; Autophagy; Biomarkers; Cells, Cultured; Chloroquine; Exoso | 2018 |
Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease.
Topics: Amodiaquine; Animals; Behavior, Animal; Chloroquine; Disease Models, Animal; Ligands; Neurogenesis; | 2015 |
Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis.
Topics: Acetylcysteine; Apoptosis; Chloroquine; Gene Knockdown Techniques; Humans; Hydrogen Peroxide; Leucin | 2010 |
[Treatment of parkinsonism with delagil].
Topics: Adult; Aged; Chloroquine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1972 |